Physician profile
Jason H Trager
NPI 1063535417
$3,826.51
in general payments reported to CMS, 2019-2025
31 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,214 · 2020: $166 · 2021: $191 · 2022: $355 · 2023: $809 · 2024: $903 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $669.46 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $499.51 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $477.46 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $301.75 | 2019-2025 | Lifevest |
| Amgen INC. | $248.98 | 2019-2024 | Repatha |
| Pfizer INC. | $203.80 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $175.02 | 2019-2024 | Farxiga, Brilinta |
| Merck Sharp & Dohme LLC | $129.12 | 2023-2025 | Verquvo, Bridion |
| Esperion Therapeutics, INC. | $103.95 | 2021-2024 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $94.89 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $89.89 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $77.35 | 2019 | |
| Novo Nordisk INC | $71.14 | 2019-2024 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $70.32 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $65.43 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $57.45 | 2019-2020 | |
| Boston Scientific Corporation | $56.91 | 2023-2024 | Watchman Access System |
| Kiniksa Pharmaceuticals International, Plc | $55.41 | 2024 | Arcalyst |
| Abiomed | $53.34 | 2024 | Impella |
| Sanofi-Aventis U.S. LLC | $53.25 | 2019 | |
| Gilead Sciences, INC. | $43.88 | 2019 | |
| Vifor Pharma, INC. | $39.95 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.21 | 2023 | |
| Bracco Diagnostics INC. | $29.59 | 2025 | |
| Scpharmaceuticals INC. | $23.99 | 2023 | |
| Exact Sciences Corporation | $21.16 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $19.69 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Kiniksa Pharmaceuticals, LTD. | $17.25 | 2023 | Arcalyst |
| Daiichi Sankyo INC. | $15.32 | 2019 | |
| Irhythm Technologies, INC. | $14.99 | 2023 | Zio Xt Patch |
| Astellas Pharma US INC | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Trager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.